Solara Active Pharma Sciences Limited - Asset Resilience Ratio

Latest as of September 2025: 0.74%

Solara Active Pharma Sciences Limited (SOLARA) has an Asset Resilience Ratio of 0.74% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Rs169.30 Million
≈ $1.83 Million USD Cash + Short-term Investments

Total Assets

Rs22.93 Billion
≈ $248.03 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2025)

This chart shows how Solara Active Pharma Sciences Limited's Asset Resilience Ratio has changed over time. Check SOLARA strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Solara Active Pharma Sciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SOLARA stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs37.10 Million 0.16%
Short-term Investments Rs132.20 Million 0.58%
Total Liquid Assets Rs169.30 Million 0.74%

Asset Resilience Insights

  • Limited Liquidity: Solara Active Pharma Sciences Limited maintains only 0.74% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Solara Active Pharma Sciences Limited Industry Peers by Asset Resilience Ratio

Compare Solara Active Pharma Sciences Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Takeda Pharmaceutical Company Limited
F:TKDA
Drug Manufacturers - Specialty & Generic 0.69%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
Drug Manufacturers - Specialty & Generic 2.04%
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
Drug Manufacturers - Specialty & Generic 0.01%
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
Drug Manufacturers - Specialty & Generic 7.85%
Jw Pharmac
KO:001060
Drug Manufacturers - Specialty & Generic 3.65%
Kamada
TA:KMDA
Drug Manufacturers - Specialty & Generic 0.00%
Samjin Pharm
KO:005500
Drug Manufacturers - Specialty & Generic 0.25%

Annual Asset Resilience Ratio for Solara Active Pharma Sciences Limited (2018–2025)

The table below shows the annual Asset Resilience Ratio data for Solara Active Pharma Sciences Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 0.74% Rs164.70 Million
≈ $1.78 Million
Rs22.32 Billion
≈ $241.37 Million
+0.42pp
2024-03-31 0.32% Rs75.80 Million
≈ $819.75K
Rs23.51 Billion
≈ $254.25 Million
-0.44pp
2023-03-31 0.76% Rs221.20 Million
≈ $2.39 Million
Rs28.99 Billion
≈ $313.52 Million
-1.03pp
2022-03-31 1.79% Rs528.70 Million
≈ $5.72 Million
Rs29.53 Billion
≈ $319.30 Million
-6.74pp
2021-03-31 8.54% Rs2.23 Billion
≈ $24.13 Million
Rs26.14 Billion
≈ $282.65 Million
+5.28pp
2020-03-31 3.25% Rs700.50 Million
≈ $7.58 Million
Rs21.54 Billion
≈ $232.89 Million
+3.12pp
2019-03-31 0.13% Rs25.98 Million
≈ $280.96K
Rs19.60 Billion
≈ $211.97 Million
+0.34pp
2018-03-31 -0.21% Rs-38.17 Million
≈ $-412.79K
Rs18.22 Billion
≈ $196.99 Million
--
pp = percentage points

About Solara Active Pharma Sciences Limited

NSE:SOLARA India Drug Manufacturers - Specialty & Generic
Market Cap
$201.79 Million
Rs18.66 Billion INR
Market Cap Rank
#16463 Global
#864 in India
Share Price
Rs515.85
Change (1 day)
+0.45%
52-Week Range
Rs425.55 - Rs686.50
All Time High
Rs1807.78
About

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. The company offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arr… Read more